For this randomized, controlled, open-label study of Drug X in combination with Drug Y compared with Y alone as first- and second-line treatment for HER2 positive, hormonereceptor positive metastatic breatst cancer, Quintiles conducted a feasibility assessment, qualified 40 new sites in eight countries, and in fewer than 12 months after the new sites were in place, Quintiles exceeded its target of 49 patients – more than doubling the sponsor's previous enrollment rate. Learn more.